It’s been another exciting year of growth at FIND India. This year, we took major strides by initiating our country’s largest ever private sector engagement project for tuberculosis (TB) control along with our partners - William J Clinton Foundation and the Centre for Health Research and Innovation. The Joint Effort for Elimination of Tuberculosis (JEET) project is funded by the Global Fund and aims to extend quality TB services to patients accessing care in the private sector. It follows the National Strategic Plan (NSP) mantra of “going where the patients go”. FIND is also supporting the expansion of the Revised National Tuberculosis Control Programme’s (RNTCP) laboratory network through the development of another 20 liquid culture and drug susceptibility testing (C&DST) laboratories, and the addition of whole genome sequencing capability within the programme.

The year 2018 also witnessed a global transformation in the hepatitis C treatment landscape with the introduction of potent, well-tolerated, all-oral regimens capable of achieving cure rates of more than 90% with 12 weeks of treatment. While large-scale manufacturing of new regimens has provided access to affordable treatments in countries including India, rapid, inexpensive and accurate diagnosis remains a critical bottleneck that must be addressed to eradicate hepatitis C. This is exactly what we are trying to achieve through the Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project, with focussed interventions in the states of Delhi, Punjab and Manipur.

Other key projects that kicked off this year include the Antimicrobial Resistance (AMR) Diagnostic Use Accelerator. This project is designed to evaluate a package of diagnostic interventions in several low- and middle-income countries in Africa and Asia, including India. Dr Sarabjit Chadha, whom we welcomed to the FIND India senior leadership team this year as Regional Technical Director, is coordinating work across four Indian study sites.

Our biggest challenge and opportunity, as a global non-profit organization, continues to be making affordable diagnostics accessible to all those who need them. This means that “access” must be considered at every step of the disease continuum.

I am also pleased to let you know that in 2018, FIND India received prior permission under the Foreign Contribution (Regulation) Act (FCRA), allowing us to receive funding from outside of India.

As always, I would like to express our gratitude to our collaborators, donors, central and state governments, and most importantly our staff for their commitment, energy and drive, and for making diagnostics matter!

Dr Sanjay Sarin
Head of FIND India
FIND INDIA AT A GLANCE

HO IN NEW DELHI + STRATEGIC PRESENCE IN 5 STATES, ENABLING PROJECTS COUNTRY-WIDE

KEY PROJECTS:
- RNTCP laboratory network – pan India
- JEET – 6 states + 1 Union Territory
- HEAD-Start – Delhi + 2 States
- AMR Dx Use Accelerator – 4 states

FIND INDIA: 87
Extended team (third-party employed): 412

PARTNER NETWORK
Donors: 8
Partners: 12+

OVERALL TEAM STRENGTH: 499

FIND TEAM MEMBERS PERSPECTIVES

“I have been with FIND since August 2010 – almost since the inception of the FIND India office. I have seen the organization grow from a Liaison Office to Sec-8 registered company and a major player in the healthcare sector.

As time has passed we have grown considerably – today we have multiple projects and a strong pool of technical and operational staff with great expertise in their respective fields. The experiences I have gained along the way are irreplaceable, adding value to my career as well as my personal growth. Every day I work with dedicated and committed co-workers across different fields. Everything here is a team effort and each day presents a new challenge!

In a nutshell, it has been a huge privilege working with FIND for the last 9 years. FIND offered new learning opportunities and enabled strengthening of inherent skills. With its rich and diverse organizational culture, I feel that my peers are best in class and that FIND is truly an ‘employer of choice’. I treasure my association with FIND and wish the organization all the best for its continued growth and success in the days and years to come.”

Ramesh Mahadevan, Logistics Officer

“I have over a decade-long association with the organization working within the admin team. As one of the first employees with the FIND India office, I have gained enormous experience and enriched my skills.

Before joining FIND, I had field-based experience of working with the Central TB Division and earlier with an advertising agency. FIND offers an employee-friendly environment along with very supporting co-workers. I take the opportunity to thank everyone including my co-workers for this enriching experience. The organization has grown over the last several years and my hope is that FIND continues to contribute to transforming lives.”

Arman Singh, Data Entry Operator

TABLE OF CONTENTS

Key projects in numbers
- RNTCP laboratory network – pan India 7
- JEET – 6 states + 1 Union Territory 9
- HEAD-Start – Delhi + 2 States 10
- AMR Dx Use Accelerator – 4 states 11

Driving efforts to eliminate TB
- Partnering to transform the diagnosis of multidrug-resistant TB 12
- Creation of laboratory-based e-training packages for the Central TB Division 13
- GeneXpert® EQA programme for public and private sector sites 14
- Contributing to national capacity for diagnostic development and manufacturing 15
- Joint Effort for Elimination of Tuberculosis (JEET) 16
- Accelerating access to quality TB diagnosis and care for children 17

Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) 18

HEAD-Start 19

AMR 20
- AMR Dx Use Accelerator 21

FIND India team 22

Looking ahead 23

Financial figures 24

Our partners 25
**Key Projects in Numbers**

**Partnering to Transform the Diagnosis of Multidrug-Resistant TB (2010–ongoing)**
- ~1.7 million tested for TB and drug-resistant TB
- >1,28,450 cases of MDR-TB
- 23 states and 2 union territories
- 61 laboratories established till date
- 6 TB laboratories with whole genome and with pyro-sequencing capacity established
- 1 "Laboratory Information Management System" (LIMS) established across the RNTCP network
- 45 mobile vans procured for the RNTCP and furnished with GeneXpert

**Accelerating Access to Quality TB Diagnosis and Care for Children (2014–2018)**
- 94,415 (<15 years of age) with suspected TB were tested using GeneXpert
- 6,270 TB cases
- 10 states

**Building National Capacity for Diagnostic Development and Manufacturing (2018–ongoing)**
- 1 site in Mumbai for frozen sample testing
- 10 sites across Ahmedabad, Guwahati, Chennai and Jaipur for operational assessment of Truenat

**Joint Effort for Elimination of Tuberculosis (JEET) (2018–ongoing)**
- > 28,000 TB patients have been notified through JEET (April 2018 to December 2018)
- 6 states being covered by FIND

**Driving Efforts to Eliminate Hepatitis C**

**GeneXpert EQA Programme for Public and Private Sector Sites (2016–ongoing)**
- 200 laboratories reached

**Head-Start (2017–ongoing)**
- 3,992 no of screening tests conducted
- 752 no of confirmatory tests conducted
- 1 state

**Creation of Laboratory-Based E-Training Packages for the Central TB Division (2017–2019)**
- 14+ hours of content developed

*For projects that are ongoing, the numbers were calculated until 31 December 2018*
Tuberculosis (TB) continues to be a major public health challenge in India, which accounts for a quarter of the world’s 10 million annual TB cases according to the World Health Organization (WHO). India has an ambitious target to eliminate TB by 2025 – a vision that is supported by the highest levels of government.

FIND is a key implementing partner of the Central TB Division (CTD), Ministry of Health & Family Welfare, Government of India, to strengthen and expand TB laboratory diagnostic capacity within the Revised National TB Control Programme (RNTCP). FIND has a comprehensive portfolio of projects to support the government’s vision.
Partnering to transform the diagnosis of multidrug-resistant TB (2010–ongoing)

From 2010 onwards, FIND has been a key technical and implementing partner of the RNTCP for the nationwide laboratory network for drug-resistant (DR) TB diagnostic services. This initiative began in 2010 as part of the EXPAND-TB project with funding from Unitaid, complemented by funding from The Global Fund. The projects have radically changed the diagnostic landscape for the RNTCP’s management of DR-TB in India.

Through the ongoing and previous grants from The Global Fund, FIND India has supported the establishment of all 61 currently existing culture and drug susceptibility testing (C&DST) laboratories for the RNTCP, with 20 more planned as a part of the ongoing grant. FIND has ensured sustained service delivery in the national programme’s C&DST laboratories through management of laboratory reagent supplies, and maintenance of equipment as well as trained HRL. Key areas where FIND continues to provide support includes for upgradation of laboratory infrastructure, human resources, training, monitoring and supervision, supply of equipment and consumables and maintenance of equipment.

Key lab strengthening activities accomplished under the The Global Fund grant in 2018 include:

1. Establishment of 15 TB C&DST laboratories in India
2. Procurement and dispatch of 45 medical mobile vans fitted with GeneXpert MTB/RIF for the early diagnosis of MDR-TB and TB in high risk populations through active case finding (ACF)
3. Support for the RNTCP in its endeavour to modernize its diagnostic network through the introduction of 5 genome sequencing technologies at the National Tuberculosis Institute (NTI) Bangalore, National Institute of TB and Respiratory Diseases (NITRD) and the New Delhi TB Centre (NDBT), Grant Medical College (GMC) & Sir JJ Group of Hospitals, Mumbai and Intermediate reference laboratory (IRL) STDC, Ahmedabad. In addition, 1 pyro-sequencing facility was established at IRL Guwahati
4. Support for the sustenance of service delivery across the RNTCP’s C&DST network by providing consumables, reagents and maintenance of essential equipment and trained manpower
5. Establishment of an optimized/decentralized flow of consumable supply through development of storage hubs at 5 locations including Delhi-NITRD, Ajmer-IRL, Bangalore-IRL, Chennai-IRL, Ahmedabad-IRL and Guwahati-IRL
6. ISO 15189 accreditation of 11 RNTCP laboratories

To help establish uniformity across the RNTCP’s laboratory network, minimize data-entry errors and automate notifications, FIND is currently rolling out a Laboratory Information Management System (LIMS) at all 61 C&DST laboratories across the RNTCP network and integrating it with RNTCP’s Nikshay web-portal.

In 2018:
- Total number of tests conducted: 5,10,977
- Diagnoses of MDR-TB: 9,305
- Diagnoses of XDR-TB: 4,389

Overall, as a part of the current grant from The Global Fund (2018–2021), FIND is focusing on the following activities:
- Sustaining service delivery in the existing C&DST and line-probe assay (LPA) laboratories
- Enhancing capacity for quality assured diagnosis of DR-TB by establishing 20 additional C&DST facilities
- Establishing LIMS for all C&DST laboratories under the RNTCP

Creation of laboratory-based e-training packages for the Central TB Division (2017–2019)

In line with the recommendations of the Assessment of India’s TB Diagnostic Network, carried out through international and national experts supported by the USAID-funded Challenge TB project, initiatives were undertaken to develop an e-training curriculum for laboratory staff.

Towards the end of 2018, FIND began development of a comprehensive set of e-training modules for four TB diagnostic technologies (sputum microscopy, GeneXpert, LPA and culture and DST-liquid and solid) and laboratory-related bio-safety practices.

In the last quarter of 2018, a multi-stakeholder workshop was organized at the National TB Institute (NTI) in Bangalore to finalize the e-training content and work towards building e-modules for the training of NTP personnel. Subject matter experts from the National Reference Laboratories, Intermediate Reference Laboratories and partners convened to update a knowledge map designed by the RNTCP. Following this workshop, the knowledge map underwent several revisions and received formal approval from the CTD. The map was subsequently used for the development of e-training content.
GeneXpert EQA programme for public and private sector sites (2016–ongoing)

External quality assurance (EQA) measures are designed to ensure that high quality laboratory testing is carried out efficiently and without interruption. In this regard, FIND India has been working to enhance and scale up EQA activities for GeneXpert.

GeneXpert is a point-of-care molecular platform that has changed the landscape of TB diagnosis and drug-susceptibility testing: time taken to obtain a test result has been reduced from months to less than 2 hours. India’s National TB Programme over the last decade has rapidly expanded the number of the GeneXpert machines and currently has over 1200 GeneXpert machines in the country. In order to deliver quality-assured service, it is critical that these laboratories have a strong quality management system (QMS).

In collaboration with the CTD, Ministry of Health & Family Welfare, Government of India, US CDC, WHO India, SHARE India, PATH and NTI, FIND supported RNTCP introduce a comprehensive GeneXpert EQA programme for public sector sites across the country in a phased manner using CDC’s Dried Tube Specimen (DTS) technology. It scaled up from 20 pilot sites to ~200 sites in 2018 and plans to cover all sites by end of year 2019.

This project has successfully established in-country capability for manufacturing large volumes of proficiency testing panels to cater to the need of the country.

Based on the first two rounds in 2018, programme managers strongly acknowledged the need for EQA for GeneXpert to monitor the quality of testing in the field in view of its exponential growth in its installation base in India over last 2–3 years.

Simultaneously, as GeneXpert EQA was being introduced in public sector sites in country, through the TB REACH Wave 5 project, CTD with support of FIND, introduced EQA for selected 21 private sector sites in the three cities of Mumbai, Delhi and Bangalore. For the first time, RNTCP engaged with private sector partners on a common platform for a quality assurance programme initiative.

The project helped develop a mechanism for engaging private sector sites in country for GeneXpert EQA. Private sector sites valued the availability of panels in country by the national programme. Private sector sites appreciated the technical assistance provided under the project. In 2019, the EQA program is being scaled up to include all public and as many possible private sector sites.

Contributing to national capacity for diagnostic development and manufacturing (2018–ongoing)

Building national diagnostic capacity is a high priority. Truenat™, a molecular technology to diagnose TB and test for resistance to rifampin in under an hour, has been developed by Molbio Diagnostics Pvt Ltd, based in Goa, with development funded by Bigtec Labs, in Bengaluru. Truenat represents the most advanced TB diagnostic developed in India to date, created specifically to tackle the high TB burden in the country. The instrument is battery operated, making it portable and well suited for settings with unreliable electrical power.

FIND conducted an initial evaluation on frozen samples at 9 sites in India, along with an operational feasibility study. Assessment of Truenat assays in settings of intended use is ongoing across 4 countries, including India, to inform WHO policy recommendations.

"We participated in the TB REACH GeneXpert EQA project. This is required for the use of GeneXpert instruments for its EQA. This project helped us to apply for NABL accreditation which we could achieve, as we could improve our quality of reporting.

Drs Pratik Zariwala and Pramod Bhatlavande from Zariwala Lab in Mumbai"
Joint Effort for Elimination of Tuberculosis (JEET) (2018–ongoing)

Studies have shown that nearly half of all patients with TB in India first seek care in the private sector, where there are significant gaps across the patient-care cascade, notable diagnostic delays, irrational and non-standardized regimens and under-reporting to authorities. As a result, an estimated million cases of TB are missed in India every year.

Engaging the private sector effectively is crucial to achieving universal access to quality diagnosis and treatment for TB. The RNTCP has worked to address these challenges by mandating TB notification, developing guidelines for private sector engagement, provisioning Public–Private Mix (PPM) coordinators at a district level, prioritizing and increasing fund allocation for the private sector under the National Strategic Plan (NSP) and including provisioning of Direct Benefit Transfer (DBT). However, gaps remain and in order to meet the ambitious NSP 2017–2025 targets, intensified, continuous engagement with private sector is required.

India’s NSP for TB elimination advocates the strategy of ‘going where the patients go’ and highlights the importance of engaging private sector to improve the standards of TB care. The key objective of this project is to set up effective and sustainable structures to strengthen existing systems and seamlessly extend quality TB care to patients seeking care in private sector.

This project aims to partner with private sector physicians, laboratories and pharmacies across various states of India to establish linkages that increase identification and notification of TB, and facilitate early treatment initiation and adherence support systems for improved treatment completion rates with mechanisms to reduce catastrophic costs to patients. This innovative approach will facilitate over 1.6 million TB case notifications over 3 years, across 400 districts of India, and ensure that at least 70% of patients will be successfully treated.

This project is being implemented by FIND in 6 states of India covering a population of over 280 million people with a target of ~260,000 people across 93 districts. Over 28,000 TB patients have been notified through JEET (April 2018 to December 2018).

JEET is carried out by a consortium comprising FIND, the William J Clinton Foundation and the Centre for Health and Research and Innovation. The project contracted agencies (TB Alert India, Karnataka Health Promotion Trust and World Health Partners) at the district level to work closely with the patient and all patient touchpoints including chemists, pharmacies, clinics, providers, hospitals, laboratories, and RNTCP. Overall, the project engages with RNTCP network at national, state and district levels.

KEY ACHIEVEMENTS IN 2018:

- Memoranda of Understanding (MoUs) were signed with all three sub-recipients (SRs) – all SRs started operations in mid-2018
- Training for sub-recipient field staff was conducted among all three sub-recipients across five states (Andhra Pradesh, Karnataka, Punjab, Tamil Nadu, West Bengal)
- Overall, recruitment of more than 75% of all JEET staff was completed by end of 2018 – out of 480 total budgeted positions, 374 were on board

SIGNIFICANT NUMBERS:

- Out of 10,888 notification target of our first reporting period, total case notifications achieved were 14,925 from January to September 2018
- Total of 164 of 285 hubs (57%) were functional by the end of December 2018
- From the period July to December 2018, 2,909 samples were transported for GeneXpert testing, with an average positivity rate of 19%
- More than 5,000 providers were engaged (visited and sensitized)
In consultation with the RNTCP, and with funding support from USAID and the US CDC as part of a Challenge TB project, FIND implemented a novel paediatric TB initiative in 10 cities from 2014 to 2018, using GeneXpert MTB/RIF. Upfront GeneXpert MTB/RIF-based diagnosis was offered to all children with symptoms of pulmonary and extra-pulmonary TB from linked facilities, free of charge, through a hub-and-spoke model. Rapid specimen transport and a reporting mechanism using email and SMS were established. These sites were transitioned, in a phased manner, to the RNTCP by the end of March 2018.

The project provided a comprehensive diagnostic solution for paediatric TB in the intervention cities through high-throughput GeneXpert laboratories located within the public sector reference laboratories. Detailed mapping of potential referral institutions (both public and private) was conducted, followed by one-to-one meetings and Continuing Medical Education (CME) for these facilities/providers.

The project has been unique in several ways:
- This pilot project demonstrated the use of GeneXpert MTB/RIF as the upfront test to diagnose TB in children for the first time in India
- From its commencement, there was a specific focus on Public Private Mix (PPM) activities targeting paediatric populations in key cities, to build the paediatric diagnostic capacity not only in the public sector but also in the private sector, where a large proportion of patients access medical care, at least as a first point of contact
- For the first time a large proportion of extra-pulmonary specimens were routinely tested.

The project was also awarded the best “Public Health Initiative” prize at the India Health and Wellness Summit, hosted in New Delhi on the 7 December 2018. In addition, 6 scientific articles related the project were published in peer-reviewed journals.

**KEY RESULTS IN PAEDIATRIC TB**

- **Overall:** 94,415 children (<15 years of age) with suspected TB were tested using GeneXpert across the 10 project intervention cities
- **This resulted in diagnosis of:** 6,270 TB cases (6.6% of tests were positive)
- **The project successfully engaged:** 1,416 facilities/providers
- **Of the total TB cases detected on GeneXpert, around 9% were diagnosed as rifampicin-resistant TB**
- **Overall, the project demonstrated more than 3-FOLD increase in the microbiological detection of paediatric TB through upfront use of GeneXpert**
- **The project facilitated prompt access to quality diagnostic services. Average turnaround time for GeneXpert testing was 1 day including specimen collection, transportation, testing, and reporting**
- **89% of the children diagnosed with TB were linked to treatment**

In the last quarter of 2018, FIND’s contribution to this project was published in a World Health Organization (WHO) guidance document entitled ‘Best practices in child and adolescent tuberculosis care’ as a recommended model for replication.

The project has been unique in several ways:
- This pilot project demonstrated the use of GeneXpert MTB/RIF as the upfront test to diagnose TB in children for the first time in India
- From its commencement, there was a specific focus on Public Private Mix (PPM) activities targeting paediatric populations in key cities, to build the paediatric diagnostic capacity not only in the public sector but also in the private sector, where a large proportion of patients access medical care, at least as a first point of contact
- For the first time a large proportion of extra-pulmonary specimens were routinely tested.

The project was also awarded the best “Public Health Initiative” prize at the India Health and Wellness Summit, hosted in New Delhi on the 7 December 2018. In addition, 6 scientific articles related the project were published in peer-reviewed journals.

Hiren Vaghela – 14 years old in this photograph – at home with his family in Surat. Hiren had been ill with TB for the last three months and received treatment for one month. He lost a lot of weight and was off school for two months. This was the second time Hiren had contracted TB. The first was three years previously.
HEPATITIS C ELIMINATION THROUGH ACCESS TO DIAGNOSTICS (HEAD-START)
HEAD-Start (2017–ongoing)

The treatment landscape for hepatitis C is currently undergoing a dramatic transformation. Potent, well-tolerated, all-oral regimens achieve cure rates of more than 90% with 12 weeks of treatment. While large-scale manufacturing of new regimens has provided access to affordable treatments in countries like India, rapid, inexpensive and accurate diagnosis remains a critical bottleneck that must be addressed to eradicate hepatitis C. To address the gap in hepatitis C virus (HCV) diagnostics, FIND is the lead partner on a multi-year, four country (including India) HCV project called Hepatitis C Elimination through Access to Diagnostics (HEAD-Start), funded by Unitaid to build an efficient and sustainable public health response to HCV.

HEAD-Start aims to improve diagnosis of HCV by making it more affordable and more widely available to those in need, with a focus on serving co-infected with HIV. The goal of the project is to contribute to WHO 2030 targets for HCV: a 90% reduction in incidence, a 65% reduction in mortality and 80% of patients receiving treatment.

In India, the project aims to implement innovative models for the screening diagnosis and treatment of HIV/HCV co-infected other high-risk patients and the general population, initially using existing diagnostic platforms and direct-acting antivirals (DAAs) and then by introducing other technologies as they become available. Through this project, FIND India will provide policy makers with the evidence to develop and implement a national, sustainable HCV policy. This is the first and largest public health HCV intervention among key populations in India in Punjab and Manipur and the general population in Delhi.

The HEAD-Start project in India began at a time of increased attention and action on hepatitis by the Government of India. On 28 July 2018, the Ministry of Health and Family Welfare (MoHFW) launched the National Viral Hepatitis Control Programme (NVHCP) while observing World Hepatitis Day.

The project experienced steady progress across all the three states in 2018. Following country operational plan approvals, the FIND team advanced with partner agreements. Screening commenced in Punjab in 2018, paving the way for screening to begin in Delhi and Manipur in early 2019.

In India, HEAD-Start is being conducted in partnership with the government of Punjab, the government of NCT of Delhi, the Institute of Liver and Biliary Sciences (ILBS) and the YR Gaitonde Centre for AIDS Research and Education (YRG CARE).

A number of critical meetings and activities took place in 2018:

- Sanjay Sarin, Head of FIND India, presented the HEAD-Start project at the Annual General Meeting of the Forum of Parliamentarians on HIV/AIDS, held at Parliament House and presided by the Union Health Minister at the time, Mr. J.P. Nadda.
- FIND presented at the National Consultation on Vulnerable Communities and Viral Hepatitis.
- Sanjay Sarin, Head of FIND India, also participated in the Asian Pacific Association for the Study of the Liver Conference at Shanghai, China.
- FIND supported the national effort on HCV diagnostics by organizing a national training of trainers’ workshop with the MoHFW to train 73 trainers on HCV laboratory processes.
- FIND also conducted a photo story trip across HEAD-Start sites and partner locations to gather photographs and videos to showcase the impact of our work on healthcare workers and patients.

**PUNJAB:**
- **SETTINGS:** Secondary and primary ARV facilities
- **ACTIVITIES:**
  - Decentralization of HCV screening at community level
  - Integration of testing in decentralized settings in hepatitis C state programme with focus on hard-to-reach groups

**DELHI:**
- **SETTINGS:** Primary and community-based facilities
- **ACTIVITIES:**
  - Hub-spoke model with decentralized screening and centralized confirmation
  - Pilot combo HCV/HIV testing to improve HCV screening with innovative technologies

**MANIPUR:**
- **SETTINGS:** Integrated care centers for ARV services in people who inject drugs
- **ACTIVITIES:**
  - Decentralization of HCV screening at community level
  - Integration of testing (RDTs and POC) in decentralized settings in AIDS state program with focus on HCV/HIV co-infected

In India, HEAD-Start is being conducted in partnership with the government of Punjab, the government of NCT of Delhi, the Institute of Liver and Biliary Sciences (ILBS) and the YRG Galionte Centre for AIDS Research and Education (YRG CARE).
The AMR Diagnostic (Dx) Use Accelerator is a platform to evaluate a package of interventions and provide evidence to inform policy change that can positively impact AMR and contribute to universal health coverage (UHC).

The AMR Dx Use Accelerator will facilitate the use of new and available point-of-care diagnostics and provide a safe environment for antibiotics to enjoy a longer useful therapeutic lifespan. It complements R&D initiatives for both diagnostics and drugs from FIND, GARDP and CARB-X, by ensuring there is a robust downstream mechanism for driving uptake and implementation.

In the first instance we are focusing on interventions to improve management of children and adolescents presenting with acute undifferentiated febrile illness, by providing a package of interventions that can help healthcare professionals provide targeted treatments. The package of interventions includes promoting available diagnostic tests, clinical decision aids, and encouraging behaviour change in outpatient clinics, we aim to rationalize the use of antibiotics.

To generate empirical evidence of the impact of our package of interventions on clinical outcomes of acute febrile illness, and on reducing antibiotic prescriptions, we are running clinical trials that share a common protocol with 9 partner institutions. Of these, 3 are in Africa (Ghana, Burkina Faso and Uganda) and 6 are in Asia (Myanmar, Nepal and 4 in India).

In India, our partners are: Jan Swasthya Sahyog in Ganiyari (Chhattisgarh), ICMR-National Institute for Cholera and Enteric Diseases (ICMR-NICED) in Kolkata (West Bengal), Post Graduate Institute of Medical Education & Research (PGIMER) in Chandigarh (Punjab) and R D Gardi Medical College in Ujjain (Madhya Pradesh). The full programme in India is being conducted in collaboration with the ICMR.

The University of Oxford is supporting us with grant management, and trial monitoring and evaluation. The WHO Special Programme for Research and Training in Tropical Diseases (TDR) is providing technical support, and collaborating with us on study design and implementation. These first-wave activities are supported by UK aid from the British people, and the Swiss Agency for Development and Cooperation (SDC).
FIND INDIA TEAM

In India, we are planning to go beyond and explore infectious diseases that cause fever in different regions. Rapid point-of-care tests to identify the most common between bacterial and nonbacterial infections, and countries. These include a rapid triage test to distinguish to support the development of affordable and appropriate treatment that contributes to AMR.

A project that we are excited about is focused on screening over 20,000 prisoners in the state of Punjab for hepatitis C as a part of our HEAD-Start project. The HEAD-Start project will come to a close in 2020 and we will ensure that our learnings are shared with the global health community.

Currently, on a global front, FIND is working with partners to support the development of affordable and appropriate new tests that meet the needs of low- and middle-income countries. These include a rapid triage test to distinguish between bacterial and nonbacterial infections, and rapid point-of-care tests to identify the most common infectious diseases that cause fever in different regions. India, we are planning to go beyond and explore interventions in community settings to ensure uptake of better diagnostics.

On the TB front, we will continue to provide unique technical assistance that is building capacity and establishing new TB C&DST facilities in India, in collaboration with the RNTCP. FIND has supported the establishment of all 81 currently existing C&DST laboratories, and ensured sustained service delivery in these laboratories through management of reagent supplies and maintenance of equipment. While 20 more C&DST laboratories are currently in the pipeline in India, at least 25-30 more will be needed to meet the WHO targets and achieve the NSP goal. Our experience in this space has uniquely positioned us to provide the support required to boost the diagnostic capacity across India.

On the TB front, we will continue to provide unique technical assistance that is building capacity and establishing new TB C&DST facilities in India, in collaboration with the RNTCP. FIND has supported the establishment of all 81 currently existing C&DST laboratories, and ensured sustained service delivery in these laboratories through management of reagent supplies and maintenance of equipment. While 20 more C&DST laboratories are currently in the pipeline in India, at least 25-30 more will be needed to meet the WHO targets and achieve the NSP goal. Our experience in this space has uniquely positioned us to provide the support required to boost the diagnostic capacity across India.
FINANCIAL FIGURES

EXPENDITURE 2015–2018

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total expenditure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INR in lakhs</td>
<td>3,230</td>
<td>2,447</td>
<td>8,265</td>
<td>14,002</td>
</tr>
<tr>
<td>USD in thousands</td>
<td>5,028</td>
<td>3,626</td>
<td>12,718</td>
<td>20,429</td>
</tr>
</tbody>
</table>

1 Expenditure include activities conducted in India, funded by FIND India and FIND Switzerland

EXPENDITURE 2018

<table>
<thead>
<tr>
<th>Expenditure 2018</th>
<th>INR in lakhs</th>
<th>USD in thousands</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Building Laboratory Capacity [The Global Fund]</td>
<td>12,925</td>
<td>18,858</td>
<td>91.51%</td>
</tr>
<tr>
<td>Providing HR and Payroll Management Services [CTD]</td>
<td>950</td>
<td>1,386</td>
<td>6.78%</td>
</tr>
<tr>
<td>Indirect Expenditure</td>
<td>48</td>
<td>70</td>
<td>0.34%</td>
</tr>
<tr>
<td>TB Challenge via KNCV and Union</td>
<td>138</td>
<td>201</td>
<td>0.99%</td>
</tr>
<tr>
<td>Other</td>
<td>54</td>
<td>78</td>
<td>0.38%</td>
</tr>
</tbody>
</table>

1 Expenditure include activities conducted in India, funded by FIND India and FIND Switzerland

1. Building Laboratory Capacity [The Global Fund]
2. Providing HR and Payroll Management Services [CTD]
3. Indirect Expenditure
4. TB Challenge via KNCV and Union
5. Other
FIND India
Flat No. 6-14, 9th Floor, Vijaya Building, 17 Barakhamba Road,
New Delhi 110001, India | Tel: +91 (11) 40419500

www.finddx.org

©FIND 2019

FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. Our work bridges R&D to access, overcoming scientific barriers to technology development; generating evidence for regulators and policy-makers; addressing market failures; and enabling accelerated uptake and access to diagnostics in low- and middle-income countries (LMICs). Since 2003, we have been instrumental in the delivery of 24 new diagnostic tools. Over 50 million FIND-supported products have been provided to 150 LMICs since the start of 2015. A WHO Collaborating Centre, we work with more than 200 academic, industry, governmental, and civil society partners worldwide, on over 70 active projects that cross six priority disease areas. FIND is committed to a future in which diagnostics underpin treatment decisions and provide the foundation for disease surveillance, control and prevention.